SLE and hair loss are closely linked, with alopecia affecting a significant proportion of people living with systemic lupus erythematosus. Hair loss in SLE can range from temporary diffuse shedding during a flare to permanent scarring alopecia caused by discoid lupus of the scalp. Understanding the different types, their causes, and the treatment options available on the NHS can help patients and clinicians manage this distressing symptom more effectively — and, in the case of scarring forms, act quickly enough to preserve remaining hair follicles.

Why Systemic Lupus Erythematosus Causes Hair Loss

SLE causes hair loss through immune-mediated inflammation — driven by autoantibodies and type I interferon pathway cytokines — that directly damages hair follicles and disrupts the hair growth cycle, compounded by disease-related physiological stress and certain medications.

Not sure if this is normal? Chat with one of our pharmacists →

Systemic lupus erythematosus (SLE) is a chronic autoimmune condition in which the immune system mistakenly attacks healthy tissue throughout the body, including the skin and hair follicles. Hair loss, known medically as alopecia, is one of the more visible and distressing manifestations of SLE, affecting a significant proportion of people living with the condition. Understanding why it occurs can help patients and clinicians manage it more effectively.

The primary mechanism involves immune-mediated inflammation. In SLE, autoantibodies and inflammatory cytokines — particularly those associated with the type I interferon pathway, which is strongly implicated in cutaneous lupus — can directly damage hair follicles and disrupt the normal hair growth cycle. This inflammation may affect the scalp skin itself or target the follicular structures beneath the surface, depending on the subtype of hair loss involved.

Additionally, SLE frequently causes systemic inflammation that places significant physiological stress on the body. This stress can push large numbers of hair follicles simultaneously into the telogen (resting and shedding) phase, resulting in diffuse hair thinning.

It is also important to recognise that some medicines used to treat SLE may themselves contribute to hair changes. Cyclophosphamide, used in severe organ-threatening disease, is well recognised as a cause of significant hair loss. Methotrexate can also contribute to hair thinning. Hydroxychloroquine, by contrast, is generally considered to have a protective effect on hair in lupus and is only rarely associated with hair changes. Corticosteroids may affect hair in various ways depending on dose and duration. Nutritional deficiencies secondary to chronic illness — such as low iron or vitamin D levels — can further compound hair loss, and these should be investigated and addressed where identified.

Types of Hair Loss Associated with SLE

SLE-related hair loss includes scarring forms such as discoid lupus of the scalp (which causes permanent follicular destruction) and non-scarring forms such as lupus hair, acute diffuse alopecia, telogen effluvium, and co-existing alopecia areata.

Hair loss in SLE is not a single, uniform condition. Several distinct patterns have been identified, each with different underlying mechanisms, clinical appearances, and implications for treatment and reversibility.

Lupus-specific hair loss includes:

• Discoid lupus erythematosus (DLE) of the scalp — a scarring form of alopecia in which chronic inflammation destroys hair follicles permanently. DLE can occur in isolation or alongside systemic disease and typically presents as well-defined, scaly, erythematous plaques on the scalp that leave smooth, atrophic scars. Early treatment is essential to preserve remaining follicles.

• Lupus hair (non-scarring frontal alopecia) — a characteristic feature of active SLE, presenting as fragile, broken hairs along the frontal hairline. These hairs are brittle due to inflammatory damage and tend to improve as disease activity is controlled.

• Acute diffuse non-scarring alopecia — diffuse hair thinning that can occur during periods of active SLE, distinct from telogen effluvium, and directly related to disease activity rather than a secondary physiological trigger.

Non-specific hair loss associated with SLE includes:

• Telogen effluvium — diffuse shedding triggered by disease flares, physical stress, surgery, or medication changes. This is generally reversible once the underlying trigger is addressed.

• Alopecia areata — an autoimmune condition that can co-exist with SLE, presenting as patchy, well-circumscribed areas of hair loss. Given the shared autoimmune background, this overlap is recognised in dermatology literature.

Distinguishing between scarring and non-scarring alopecia is clinically important because scarring forms carry a risk of permanent hair loss if not treated promptly, whereas non-scarring types are often reversible with appropriate disease management.

How SLE-Related Hair Loss Is Diagnosed

Diagnosis requires clinical scalp examination, trichoscopy, and blood tests including ANA, anti-dsDNA, complement levels, and ferritin; scalp biopsy with prompt dermatology referral is recommended when scarring alopecia is suspected.

Diagnosing hair loss in the context of SLE requires a thorough clinical assessment that considers both the pattern of hair loss and the overall activity of the underlying disease. A detailed history is essential, including the onset and progression of hair loss, any recent disease flares, medication changes, and associated symptoms such as scalp tenderness, itching, or scaling.

Clinical examination of the scalp should assess the distribution of hair loss, the presence or absence of scarring, follicular plugging, erythema, or scaling. A dermatoscope (trichoscopy) can provide valuable information about follicular architecture and signs of inflammation without the need for invasive procedures. Where scarring alopecia is suspected — particularly discoid lupus — prompt referral to a dermatologist and a scalp biopsy are recommended to confirm the diagnosis histologically and guide treatment decisions. Early referral is important, as delay risks irreversible follicular loss.

Blood tests play an important supporting role and typically include:

• Full blood count — to identify anaemia or lymphopenia associated with active SLE

• Inflammatory markers — ESR is often elevated in active SLE; CRP may be relatively normal during a lupus flare but can be raised in the context of infection, which is a useful distinguishing feature

• Immunology — antinuclear antibody (ANA), extractable nuclear antigen (ENA) profile, complement levels (C3, C4), and anti-dsDNA antibodies to assess disease activity

• Ferritin, vitamin D, thyroid function tests — to exclude concurrent deficiencies or thyroid disease, which can independently cause hair loss

In line with NICE guidance on SLE (diagnosis and management), assessment of organ involvement and disease activity should be conducted regularly, and any new or worsening cutaneous features — including hair loss — should prompt a review of the overall disease management plan. Referral to a dermatologist with experience in autoimmune skin conditions is appropriate where the diagnosis is uncertain or scarring alopecia is suspected.

Treatment Options Available on the NHS

NHS treatment centres on controlling SLE disease activity with hydroxychloroquine as first-line; severe or refractory disease may require immunosuppressants or biologics such as belimumab or anifrolumab, with topical or intralesional corticosteroids for discoid scalp lupus.

Treatment of SLE-related hair loss on the NHS is guided by the underlying cause and the overall management of the systemic disease. In many cases, effectively controlling SLE disease activity is the most important step in reducing hair loss, as hair regrowth often follows when inflammation is brought under control.

Hydroxychloroquine (an antimalarial) is a cornerstone of SLE management and is recommended by NICE for most patients with SLE. It has well-established anti-inflammatory properties and is considered beneficial for cutaneous manifestations, including hair loss. It is generally well tolerated. In line with Royal College of Ophthalmologists guidance, patients should be prescribed hydroxychloroquine at a dose not exceeding 5 mg/kg actual body weight per day, have a baseline ophthalmological assessment before or shortly after starting treatment, and undergo annual retinal screening after five years of use (or earlier if risk factors for retinopathy are present).

For more severe or refractory disease, additional immunosuppressive agents may be used, including:

• Methotrexate or azathioprine — for moderate disease; note that methotrexate can contribute to hair thinning

• Mycophenolate mofetil — particularly for renal or severe cutaneous involvement

• Cyclophosphamide — reserved for severe organ-threatening SLE; patients should be aware that significant hair loss is a well-recognised side effect

• Belimumab (a biologic therapy targeting B-lymphocyte stimulator) — available on the NHS for active, autoantibody-positive SLE that has not responded adequately to standard treatment, in accordance with the relevant NICE technology appraisal

• Anifrolumab (a biologic therapy targeting the type I interferon receptor) — also available on the NHS for active, autoantibody-positive SLE not adequately controlled by standard therapy, in accordance with the relevant NICE technology appraisal

For discoid lupus of the scalp, topical and intralesional corticosteroids are commonly used to reduce local inflammation and prevent further follicular destruction. Topical tacrolimus may be considered as a steroid-sparing alternative; patients should be aware that its use on the scalp in this context is off-label, and it should only be used under the guidance of a specialist. Early treatment is critical in scarring alopecia to preserve remaining follicles.

Where hair loss is related to nutritional deficiencies identified on blood testing, supplementation with iron or vitamin D may be recommended alongside disease-specific treatment. Minoxidil may be considered by a clinician for non-scarring alopecia; however, its use in SLE-related hair loss is off-label and it should only be used following discussion with and recommendation from a healthcare professional.

If you experience any suspected side effects from your medicines, you can report these to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

Experiencing these side effects? Our pharmacists can help you navigate them →

Managing Hair Loss Alongside Your SLE Treatment

Practical management includes gentle hair care, high-factor sun protection, balanced nutrition, and stress reduction; NHS wig provision may be available for eligible patients, and non-scarring hair loss often improves during disease remission.

Living with hair loss as part of SLE can have a significant impact on self-esteem, body image, and mental wellbeing. Acknowledging this impact is an important part of holistic care. Patients are encouraged to discuss concerns about hair loss openly with their rheumatology or dermatology team, as it is a recognised and treatable feature of the condition rather than a cosmetic afterthought.

Practical measures to protect hair and minimise further damage include:

• Gentle hair care — using mild, sulphate-free shampoos and avoiding excessive heat styling, chemical treatments, or tight hairstyles that place traction on fragile hair

• Sun protection — UV exposure can trigger SLE flares and worsen cutaneous disease; wearing a wide-brimmed hat and using a broad-spectrum SPF 50+ sunscreen with high UVA protection (4 or 5 stars) on exposed scalp skin is advisable, alongside protective clothing

• Balanced nutrition — maintaining adequate intake of protein, iron, and vitamins supports overall hair health

• Stress management — psychological stress is a recognised trigger for SLE flares and telogen effluvium; mindfulness, gentle exercise, and access to psychological support can be beneficial

For those experiencing significant or prolonged hair loss, referral to a specialist hair clinic or a dermatologist with expertise in autoimmune conditions may be appropriate. Some patients may also wish to explore NHS wig provision. In England, wigs may be available free of charge or at a reduced cost to eligible patients; eligibility criteria and any charges vary across the four UK nations and depend on individual circumstances, including whether you are entitled to help with NHS health costs. Your GP or specialist team can advise on eligibility and how to access this service.

If you are considering seeing a trichologist privately, please be aware that trichology is not a regulated medical profession in the UK. For medical assessment and treatment of hair loss related to SLE, a consultant dermatologist or specialist hair clinic within the NHS is the most appropriate route.

It is also worth noting that hair loss in SLE tends to fluctuate with disease activity. Many patients experience regrowth during periods of remission, which can be reassuring, particularly for those with non-scarring forms of alopecia.

When to Seek Further Advice from Your Specialist

Seek prompt specialist advice if you notice sudden significant hair loss, new scalp scarring or redness, or hair loss unresponsive to treatment; seek same-day urgent advice if fever or signs of scalp infection develop whilst taking immunosuppressive medicines.

Whilst some degree of hair shedding during a lupus flare may be expected, there are specific circumstances in which patients should seek prompt advice from their rheumatologist, dermatologist, or GP rather than waiting for a routine appointment.

Contact your specialist or GP if you notice:

• A sudden or significant increase in hair loss, particularly if accompanied by other signs of a disease flare such as joint pain, fatigue, rash, or fever

• New areas of scalp redness, scaling, tenderness, or scarring, which may indicate discoid lupus requiring urgent treatment to prevent permanent hair loss

• Hair loss that is not improving despite stable disease activity and current treatment

• Psychological distress related to hair loss that is affecting daily functioning or quality of life

• Any new symptoms that could suggest a medication side effect, such as mouth ulcers, nausea, or abnormal bruising

Seek urgent same-day advice — by contacting your specialist team, calling NHS 111, or attending urgent care — if you develop a fever, signs of infection (such as increasing redness, swelling, or pain on the scalp), or rapidly expanding painful scalp lesions whilst taking immunosuppressive medicines. People on immunosuppression are at increased risk of serious infections, and prompt assessment is important.

Regular monitoring appointments with your rheumatology team are an important opportunity to review all aspects of SLE, including skin and hair changes. NICE guidance on SLE recommends that patients have their disease activity, organ damage, and treatment reviewed at least annually, and more frequently during periods of active disease.

If hair loss is a persistent concern, ask for a referral to a dermatologist with expertise in autoimmune conditions or a specialist hair clinic. Early intervention — particularly in scarring alopecia — can make a meaningful difference to long-term outcomes. You should never feel that hair loss is too minor a concern to raise; it is a legitimate and important aspect of living well with SLE.

Frequently Asked Questions